[go: up one dir, main page]

EA201201451A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA201201451A1
EA201201451A1 EA201201451A EA201201451A EA201201451A1 EA 201201451 A1 EA201201451 A1 EA 201201451A1 EA 201201451 A EA201201451 A EA 201201451A EA 201201451 A EA201201451 A EA 201201451A EA 201201451 A1 EA201201451 A1 EA 201201451A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredient
pharmaceutically active
pharmaceutical composition
present
stabilized
Prior art date
Application number
EA201201451A
Other languages
English (en)
Inventor
Ясухиро Хираиси
Мунео Нономура
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201201451A1 publication Critical patent/EA201201451A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции или твердой готовой лекарственной форме, содержащей стабилизированный фармацевтически активный ингредиент, и к способу ее стабилизации. Согласно настоящему изобретению, фармацевтическая композиция может быть стабилизирована за счет содержания непептидного фармацевтически активного ингредиента, имеющего первичную или вторичную аминогруппу, эксципиента и кислотного соединения. В дополнение, в случае твердой готовой лекарственной формы, содержащей фармацевтически активный ингредиент, оксид титана, пластификатор и связывающую органическую кислоту, может быть усилена стабильность фармацевтически активного ингредиента во время воздействия светового излучения.
EA201201451A 2008-07-28 2009-07-27 Фармацевтическая композиция EA201201451A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
EA201201451A1 true EA201201451A1 (ru) 2013-07-30

Family

ID=41327301

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201201451A EA201201451A1 (ru) 2008-07-28 2009-07-27 Фармацевтическая композиция
EA201170272A EA201170272A1 (ru) 2008-07-28 2009-07-27 Фармацевтическая композиция

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201170272A EA201170272A1 (ru) 2008-07-28 2009-07-27 Фармацевтическая композиция

Country Status (29)

Country Link
US (2) US9186411B2 (ru)
EP (2) EP2564833B1 (ru)
JP (2) JP5295356B2 (ru)
KR (1) KR20110042334A (ru)
CN (3) CN102164581A (ru)
AR (1) AR072842A1 (ru)
AU (1) AU2009277443A1 (ru)
BR (1) BRPI0916689A2 (ru)
CA (2) CA2732243C (ru)
CL (1) CL2011000170A1 (ru)
CO (1) CO6290638A2 (ru)
CR (1) CR20110110A (ru)
DO (2) DOP2011000033A (ru)
EA (2) EA201201451A1 (ru)
EC (1) ECSP11010855A (ru)
ES (2) ES2669592T3 (ru)
GE (2) GEP20146122B (ru)
IL (2) IL210735A0 (ru)
MA (1) MA32556B1 (ru)
MX (1) MX2011000757A (ru)
MY (2) MY156305A (ru)
NZ (2) NZ602592A (ru)
PE (3) PE20141585A1 (ru)
SG (1) SG186685A1 (ru)
TW (2) TW201010992A (ru)
UA (1) UA103332C2 (ru)
UY (1) UY32008A (ru)
WO (1) WO2010013823A2 (ru)
ZA (1) ZA201101198B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
AR091567A1 (es) 2012-06-27 2015-02-11 Takeda Pharmaceutical Preparacion liquida, metodo, kit de inyeccion
JP5791817B2 (ja) * 2012-09-19 2015-10-07 大鵬薬品工業株式会社 溶出性及び／又は吸収性が改善された経口投与用医薬組成物
EP2968695A1 (en) * 2013-03-14 2016-01-20 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
PH12018500236B1 (en) 2015-07-30 2023-12-06 Takeda Pharmaceuticals Co Tablet
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
CN110072518B (zh) * 2016-10-12 2021-10-26 细胞内治疗公司 无定形固体分散体
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
MX2019014201A (es) 2017-05-31 2020-01-23 Boehringer Ingelheim Int Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
KR102747118B1 (ko) * 2017-07-10 2024-12-26 다케다 야쿠힌 고교 가부시키가이샤 보노프라잔을 포함하는 제제
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
HUE062608T2 (hu) * 2020-04-24 2023-11-28 Dr Falk Pharma Gmbh Egy piridinon-származék szisztémás formulázása lisztérzékenység kezelésére
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743A (zh) * 2023-01-18 2023-04-11 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2003011296A1 (en) 2001-07-30 2003-02-13 Mitsubishi Pharma Corporation Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
KR20050037405A (ko) 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
US7247702B2 (en) 2002-02-28 2007-07-24 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
SI1485094T2 (sl) 2002-03-07 2020-08-31 Boehringer Ingelheim International Gmbh Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
EP1648416A4 (en) 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
WO2005094812A1 (ja) 2004-04-01 2005-10-13 Ajinomoto Co., Inc. ナテグリニド含有製剤
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
CA2582777A1 (en) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Proton pump inhibitors
WO2006037766A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
JP5188181B2 (ja) 2005-08-25 2013-04-24 協和発酵バイオ株式会社 血中アルコール濃度上昇抑制用組成物
BRPI0615111B8 (pt) * 2005-08-30 2021-05-25 Takeda Pharmaceuticals Co composto, composição farmacêutica, e, uso do composto
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
US20100062063A1 (en) 2006-09-15 2010-03-11 Astellas Pharma Inc. Light-stable solid pharmaceutical composition of ramosetron
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009041447A1 (ja) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited ５員複素環化合物
TW200920366A (en) 2007-09-28 2009-05-16 Takeda Pharmaceutical 5-membered heterocyclic compound
US20110059176A1 (en) 2007-11-22 2011-03-10 The University Of Tokyo Material for preventing tissue adhesion and material for preventing joint contracture

Also Published As

Publication number Publication date
CA2936400C (en) 2018-03-27
TW201010992A (en) 2010-03-16
NZ602592A (en) 2014-01-31
TW201431552A (zh) 2014-08-16
JP2013047239A (ja) 2013-03-07
US9186411B2 (en) 2015-11-17
WO2010013823A3 (en) 2010-04-15
US20110124687A1 (en) 2011-05-26
CO6290638A2 (es) 2011-06-20
BRPI0916689A2 (pt) 2015-11-17
NZ591344A (en) 2013-03-28
CN102743330B (zh) 2016-03-23
MY169461A (en) 2019-04-11
SG186685A1 (en) 2013-01-30
EP2564833A1 (en) 2013-03-06
WO2010013823A2 (en) 2010-02-04
MA32556B1 (fr) 2011-08-01
EP2564833B1 (en) 2017-12-20
DOP2011000033A (es) 2011-04-15
ZA201101198B (en) 2012-05-30
GEP20146122B (en) 2014-07-25
PE20141585A1 (es) 2014-11-13
EP2309985A2 (en) 2011-04-20
ES2669592T3 (es) 2018-05-28
CR20110110A (es) 2011-04-28
CA2732243A1 (en) 2010-02-04
JP5593363B2 (ja) 2014-09-24
MX2011000757A (es) 2011-02-24
MY156305A (en) 2016-01-29
PE20140977A1 (es) 2014-08-20
AR072842A1 (es) 2010-09-22
CA2732243C (en) 2016-11-29
IL228817A0 (en) 2013-12-31
CL2011000170A1 (es) 2011-06-10
UA103332C2 (ru) 2013-10-10
EA201170272A1 (ru) 2011-10-31
DOP2013000172A (es) 2013-11-15
GEP20146166B (en) 2014-09-25
ES2660962T3 (es) 2018-03-26
KR20110042334A (ko) 2011-04-26
JP5295356B2 (ja) 2013-09-18
ECSP11010855A (es) 2011-03-31
IL210735A0 (en) 2011-03-31
US20130261156A1 (en) 2013-10-03
UY32008A (es) 2010-02-26
AU2009277443A1 (en) 2010-02-04
EP2309985B1 (en) 2018-03-14
JP2011529445A (ja) 2011-12-08
PE20110591A1 (es) 2011-09-15
CN102164581A (zh) 2011-08-24
CA2936400A1 (en) 2010-02-04
CN102743330A (zh) 2012-10-24
CN104784180A (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
EA201201451A1 (ru) Фармацевтическая композиция
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CY1118183T1 (el) Φαρμακευτικη μορφη δοσης η οποια περιεχει νιφεδιπινη ή νισολδιπινη και εναν ανταγωνιστη αγγειοτενσινης ιι ή/και ενα διουρητικο
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CO6290639A2 (es) Composicion farmaceutica mejorada que contiene dihidropiridina antagonista del canal de calcio y el metodo para su preparacion
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
UA104136C2 (ru) Фармацевтическая композиция, которая включает ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, и способ ее получения
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
CY1123382T1 (el) Απο του στοματος και ενεσιμα και σκευασματα ενωσεων τετρακυκλινης
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA200702637A1 (ru) Производные пурина
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA201391406A1 (ru) Лекарственные формы отамиксабана с улучшенной стабильностью
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
TR201004754A1 (tr) Yeni Farmasötik Kombinasyonlar
EA201001871A1 (ru) Гастрорезистентные пероральные фармацевтические композиции, содержащие дулоксетин или его фармацевтически приемлемые производные
TN2011000030A1 (en) Pharaceutical composition
CY1113140T1 (el) Στερεα μορφη δοσης απο του στοματος, που περιεχει τον αντιαιμοπεταλιακο παραγοντα κλοπιδογρελη, και μεθοδος για την παρασκευη αυτης